De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

It might ap­pear as though the pri­vate biotech sec­tor is ap­proach­ing a thaw. In re­cent weeks, a Flag­ship start­up raised $273 mil­lion, an RNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.